Literature DB >> 10767109

Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease.

.   

Abstract

Localized regulation of fibrinolytic protein gene expression is associated with the histologic extent of atherosclerosis. This regulation may be dependent on the presence of certain fibrinolytic protein gene polymorphisms. The relationship between the plasminogen activator inhibitor (PAI)-1 Hin dIII and the tissue plasminogen activator (t-PA) EcoR1 gene polymorphisms and the extent of coronary artery disease (CAD) were investigated in 49 Caucasian patients with symptomatic CAD. There was a strong association between PAI-1, but not t-PA, gene polymorphisms and the extent of CAD detected by coronary angiography. Patients homozygous for the presence or absence of the PAI-1 HindIII (1/1, 2/2 PAI-1) gene polymorphisms had a significantly greater extent of CAD (number of diseased vessels) than patients with the respective heterozygous forms (vs. 1/2 PAI-1, P&< = 0.05). Stepwise ordinal multiple regression analysis of classic CAD risk factors and fibrinolytic protein genotypes indicated that only the PAI-1 genotypes were predictive of the extent of angiographic CAD (P = 0.019). Analysis of variance between classic risk factors and fibrinolytic protein genotypes identified an association between t-PA genotypes and a history of prior infarction or stroke. Fibrinolytic gene polymorphisms for PAI-1 are associated with the extent of CAD in symptomatic patients and with certain risk factors for coronary atherosclerosis.

Entities:  

Year:  1998        PMID: 10767109     DOI: 10.1023/A:1008882113177

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  40 in total

1.  Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.

Authors:  J Mehta; P Mehta; D Lawson; T Saldeen
Journal:  J Am Coll Cardiol       Date:  1987-02       Impact factor: 24.094

2.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

Review 3.  The fibrinolysis and coagulation systems in ischaemic heart disease. Risk markers and their relation to metabolic dysfunction of the arterial intima.

Authors:  J Jespersen; S Munkvad; J B Gram
Journal:  Dan Med Bull       Date:  1993-09

4.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.

Authors:  J Aznar; A Estellés; G Tormo; P Sapena; V Tormo; S Blanch; F España
Journal:  Br Heart J       Date:  1988-05

5.  Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.

Authors:  A Hamsten; U de Faire; G Walldius; G Dahlén; A Szamosi; C Landou; M Blombäck; B Wiman
Journal:  Lancet       Date:  1987-07-04       Impact factor: 79.321

6.  The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.

Authors:  S Ye; F R Green; P Y Scarabin; V Nicaud; L Bara; S J Dawson; S E Humphries; A Evans; G Luc; J P Cambou
Journal:  Thromb Haemost       Date:  1995-09       Impact factor: 5.249

7.  Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up.

Authors:  A Fontbonne; M A Charles; N Thibult; J L Richard; J R Claude; J M Warnet; G E Rosselin; E Eschwège
Journal:  Diabetologia       Date:  1991-05       Impact factor: 10.122

8.  Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.

Authors:  B O Olofsson; G Dahlén; T K Nilsson
Journal:  Eur Heart J       Date:  1989-01       Impact factor: 29.983

9.  Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.

Authors:  K W Klinger; R Winqvist; A Riccio; P A Andreasen; R Sartorio; L S Nielsen; N Stuart; P Stanislovitis; P Watkins; R Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

10.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.

Authors:  J Schneiderman; M S Sawdey; M R Keeton; G M Bordin; E F Bernstein; R B Dilley; D J Loskutoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

View more
  6 in total

Review 1.  The impact of molecular medicine upon early cardiovascular drug development.

Authors:  M W Lunnon; M Braddock
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 2.  Plasminogen activator inhibitor type-1 (part one): basic mechanisms, regulation, and role for thromboembolic disease.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

3.  Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.

Authors:  Norma Torres-Carrillo; Nora Magdalena Torres-Carrillo; Gloria Esther Martínez-Bonilla; Mónica Vázquez-Del Mercado; Claudia Azucena Palafox-Sánchez; Edith Oregón-Romero; Ana Guilaisne Bernard-Medina; Héctor Rangel-Villalobos; José Francisco Muñoz-Valle
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

4.  Plasminogen activator inhibitor-1 polymorphisms as a risk factor for chronic periodontitis in North Indian population.

Authors:  Puja Debnath; Jayant Dewangan; Divya Tandon; Vivek Govila; Mona Sharma; Virendra Kumar; Smita Govila; Srikanta Kumar Rath
Journal:  J Oral Biol Craniofac Res       Date:  2018-04-18

5.  Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children.

Authors:  Ulises De la Cruz-Mosso; José F Muñoz-Valle; Lorenzo Salgado-Goytia; Adrián García-Carreón; Berenice Illades-Aguiar; Eduardo Castañeda-Saucedo; Isela Parra-Rojas
Journal:  BMC Pediatr       Date:  2012-03-29       Impact factor: 2.125

6.  Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease.

Authors:  Afsaneh Forood; Reza Malekpour-Afshar; Amin Mahdavi
Journal:  Addict Health       Date:  2014 Summer-Autumn
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.